Core Viewpoint - The company, CloudTop New Medicine (01952.HK), has made significant progress in patent protection for its original product, Budesonide Enteric-Coated Capsules (Nai Fu Kang®), following a favorable ruling from the Guangzhou Intellectual Property Court [1] Group 1: Legal Developments - The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's pre-litigation preservation application [1] - The court ordered relevant generic drug companies to immediately cease infringement activities and stop listing their products [1] - The ruling is effective immediately upon issuance, reflecting the court's commitment to upholding intellectual property rights [1] Group 2: Company Commitment - The company expressed its welcome for the court's fair ruling and reiterated its commitment to legally protect intellectual property [1] - The company aims to promote innovative therapies to benefit more patients [1]
云顶新耀(01952.HK)：耐赋康®专利诉讼取得积极进展